درمان سرطان ريه

THE PSYCHOTHERAPEUTIC POINT OF VIEW OF PSYCHEDELIC-ASSISTED TREATMENT

The psychotherapeutic setting offers a highly controllable and supportive environment that most likely differs from the patient's other past and present environments. As time passes, the patient regularly exposed to this therapeutic environment gradually adapts to it. In doing so, it slowly updates its high-level forecasts that were formed in less controllable environments and therefore indicate large uncertainty. Because the therapeutic environment strongly contradicts the rigid prediction of uncontrollability and uncertainty, the sensory prediction error becomes larger and larger. At a certain point, the sensory inputs that signal safety and support can no longer be explained, initiating an updating process.

Psychedelics appear to amplify the restorative effect of real relationships. From a psychological point of view, we have already said that psychedelics tend to increase feelings of connection with the therapist. The socializing effect of MDMA is typical.

Psychedelics (to some extent) give us what we expect to get from them, like a placebo. This is not a new idea. Weil (1972) described psychedelics as a kind of active placebo: while they certainly do something, most of what it is may come from the users themselves.

Grof (2008) argues that “psychedelics function more or less as nonspecific catalysts and amplifiers of the psyche.” Finally, Matthew Johnson, quoted by Pollan (2018) says about psychedelic treatment: “Whatever we are delving into here, it is in the same realm as placebo. But a placebo on a rocket.”

Psychotherapy has also been described as a placebo (open-label). Consequently, we can say that a psychedelic session enhances the placebogenic effects of psychotherapy, making psychedelic-assisted treatment a sort of super placebo.

Psychotherapy (co)defines a patient's set and setting, i.e. his internal and external environment: it induces expectations of repair and provides a safe environment. When the brain enters an anarchic state due to the supposed effects of psychedelics, the bottom-up signals sent from these internal and external environments become more influential. In this way, the patient should be able to transfer the safety and controllability of the therapeutic environment to his own generative model, enhancing the path of the real relationship. Similarly, psychedelics also appear to enhance the expectation pathway.

On the one hand, it is hypothesized that the impact of restorative expectations is less limited by higher-level forecasts. Any positive basic feelings and attitudes a patient may have towards a psychedelic experience tend to be amplified with psychedelics.

Magic mushrooms and mental health

The effects of psilocybin and psilocin on the brain may have therapeutic potential for treating mental health conditions such as depression, anxiety, addiction, and post-traumatic stress disorder (PTSD). Psilocybin mushrooms may help people break free from rigid and negative patterns of thinking and behavior by increasing creativity, flexibility, and openness. Psilocybin may also help people access and process traumatic memories and emotions by reducing the fear response and increasing empathy and compassion. Several studies have shown that psilocybin can produce lasting improvements in mood, well-being, and quality of life in patients with depression 3 , anxiety 4 , addiction 5 , and PTSD. Psilocybin may also induce mystical or spiritual experiences that can have profound and positive effects on a person's worldview, values, and meaning in life.

Addiction and dangers of magic mushrooms

Magic mushrooms and psilocybin are non-addictive and have very little risk of physical harm or toxicity. However, Magic Mushroom can cause unpleasant or challenging effects such as anxiety, paranoia, confusion or psychosis. These effects are influenced by the dose, personality, conditions of use, expectations and psychological state of the individual.

Therefore, it is better to use Magic Mushroom with caution and under professional guidance in a safe and comfortable environment. Research on the effects of psilocybin on the body continues, but no serious physical risks have been reported in the use of magic mushroom, and there is no possibility of overdose with this mushroom. For more information on this topic, is it possible to overdose with magic mushrooms? read the

Magic mushroom and treatment of depression

In a 2012 study, David Knott, a neuroscientist at Imperial College London, found that in depressed people, connections between brain circuits in certain areas were stronger. In an interview with Psychology Today, Professor Nott says: "People who suffer from depressive thinking, their brains are over-connected, and they experience obsessive and overwhelming negative thoughts and feelings of self-criticism. Professor Nutt explains that the psilocybin mushroom can provide powerful relief by loosening these connections and creating new connections.

There are many doctors and psychiatrists who are not so sure about legalizing magic mushrooms for treatment. They believe that it may take more time to reveal the side effects of Magic Mushroom and it is still too early to comment on this. Especially now that all the treatments are done under the control and supervision of special people and it is not known what fatal side effects will be caused by using it individually.

"Right now, there aren't many options for using magic mushrooms," says Dr. Shimi Kang, a Vancouver psychiatrist who was the principal investigator of Canada's first study of magic mushrooms and their effects on treatment-resistant depression. One option is special access, where the patient and doctor must prove they've tried every other treatment and get special approval. This is a private job, so it's out of pocket. A second option is to go through research studies or Clinical Trials Using Psilocybine at one of the Toronto academies we just heard about. These are free, however, there is no guarantee that you can easily participate in these schemes and there are quite strict criteria. In addition, we have all seen how people in situations are under very controlled and monitored conditions.

"I say don't do it," he says of legalizing magic mushrooms for everyone. These plants are very powerful. Yes, magic mushrooms are natural! We know that when used well, they can have profound health effects, we see that, but when used incorrectly, in the wrong dose at the wrong time, without taking into account the interactions of appropriate medical supervision for other diseases or drugs, it can cause complications. have a very serious negative side. It is true, however, that these are generally safe when consumed appropriately by appropriately experienced and trained individuals who know how to make these trips."

According to him, as a psychiatrist with 20 years of experience, the use of Magic Mushroom legally requires more and deeper studies. It should not be repeated with a quick decision the problems that have been created with other psychedelics.

Extemporaneous compounding of MDMA and psilocybin products

Pharmacists should consider the guidelines on compounding of medicines. See the Pharmacy Board of Australia codes, guidelines and policies- external site. The guidelines include detailed guidance on when it is appropriate for a medicine to be compounded and the requirements to be complied with when compounding medicines.

Pharmacists should be aware:

MDMA and psilocybin products are controlled drugs under the Commonwealth Criminal Code. This means MDMA and psilocybin cannot be possessed, manufactured or supplied unless authorised by law.

The exemptions under the Therapeutic Goods Act 1989 that permit pharmacists to engage in extemporaneous compounding do not amount to an authorisation under the Criminal Code.

Compounding by pharmacists may be unlawful in some states and territories. If the pharmacy licensing arrangements in the relevant state or territory do not authorise the compounding of MDMA and psilocybin products (e.g., if they do not authorise the compounding of Schedule 8 or Schedule 9 substances) and there is no separate authority that applies, the compounding of such goods will contravene the Commonwealth Criminal Code. Hence, pharmacists should seek advice from their state or territory health department prior to engaging in extemporaneous compounding of MDMA or psilocybin containing products.

Prescribers and pharmacists should also consider individual legal and professional responsibilities when a compounded medicine is prescribed and subsequently compounded and dispensed.

It is expected that pharmacists will use Natural Pharmaceutical Grade Psychedelics ingredients that comply with quality standards.

Quality standards

There are currently no pharmacopeial monographs for MDMA or psilocybin. The TGA will develop quality standards based on the active ingredients and finished products currently being supplied to clinical trials. These standards (Therapeutic Goods Orders, TGO) will ensure consistent quality of the medicines supplied to Australian patients. The requirements will apply to both compounded and commercially manufactured medicines.

GMP licensed pharmacy 

TGA GMP licensed compounders will need a new authorisation on their licence to compound MDMA or psilocybin. These licences will be conditioned to require reporting on the quantities these goods manufactured and held at the premises, as required under Australia’s international obligations. 

Any site applying for a new TGA GMP licence will similarly require the specific authorisations under that licence to manufacture MDMA or psilocybin medicines and have conditions to report on the quantity of goods held and supplied.

VANCOUVER, British Columbia, Nov. 16, 2022 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla”)(CSE: MDMA), a biotechnology company focused on the research, development, and manufacturing of MDXX class molecules, including MDMA, and Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) ("Mindset"), a drug discovery company developing novel, optimized, next-generation psychedelic and non-psychedelic medications to treat neuropsychiatric and neurological disorders with unmet medical needs, today announced that they have entered into an exclusive sales agreement. Under the sales agreement, PharmAla will be the exclusive global reseller of Mindset’s cGMP (i.e. pharmaceutical grade) psilocybin to appropriately licensed clinical researchers.

“In addition to forging new ground in next generation psychedelic drug discovery, Mindset has also developed a patent-pending, highly scalable psilocybin synthesis technology. A غير مجاز مي باشدt-effective supply of first generation psychedelic therapeutics is essential to the overall development of the medical psychedelic space, and Mindset is eager to help meet this increased demand for pharmaceutical grade psilocybin from researchers,” said James Lanthier, CEO of Mindset. “We have chosen PharmAla as a partner because of their track record in working with clinical researchers, and existing sales infrastructure to sell Pharmaceutical Grade Psychedelics compounds. It’s also yet another concrete example of Mindset commercializing and creating value from its portfolio of innovations.”

Mindset has recently completed production of a large batch of cGMP psilocybin at the U.S. site of an international contract development and manufacturing company (“CDMO”) pursuant to the annual DEA quota on psilocybin.

“While we have until now focused exclusively on MDMA and its analogues, we’ve heard time and again that our clinical partners want access to other research materials. We see significant synergies in this partnership with Mindset; our sales infrastructure, as well as our Canadian pharmaceutical value chain, can create revenue opportunities for both companies,” said Nick Kadysh, CEO of PharmAla. “With the culmination of this agreement, we’re the first and only organization that is able to offer the clinical research community two of the most high-quality and in-demand APIs in Psychedelics: PharmAla’s GMP LaNeo™ MDMA, and Mindset’s cGMP Psilocybin.”

Magic mushroom or psilocybin mushroom grows in different tropical regions of the world and is considered a hallucinogenic drug. You might ask, what is a mushroom? What are the side effects of using Magic Mushroom? In this article, we will talk about mushroom drugs in general, or hallucinogenic mushrooms. Stay with us until the end of the article to get answers to your questions.

What is magic mushroom?

Magic mushroom or psilocybin, which is more commonly known as magic mushroom or mushroom. These mushrooms are hallucinogens that contain the chemical psilocybin. Mushroom drugs are very popular among people because of their psychoactive effects. Psilocybin was first discovered in 1958 by Dr. Albert Hoffman. There are different types of these magic mushroom drugs, each of which has a different dose of psilocybin. Sometimes they are confused with poisonous mushrooms, so it is necessary to know the types of mushrooms.

Some mushrooms are cultivated in indoor environments or they are wild. Hallucinogenic mushrooms contain two types of psilocybin and psilocin compounds. Psilocybin is the main psychoactive compound in these mushrooms, and psilocybin is found in a smaller amount in them, but it is stronger than psilocybin. By eating hallucinogenic mushrooms, psilocybin is converted into psilocin after being metabolized.

Types of magic mushrooms or hallucinogenic mushrooms

There are about 200 species of psychedelic mushrooms around the world, which have different names and are usually classified according to their biological genus. Among the most common ones are Psilocybin, Gymnopilus, Panaeolus and Copelandia, which are found all over the world. In general, hallucinogenic or psychedelic mushrooms are mushrooms with dark spores and gills that grow in the forests of subtropical and tropical regions.

How to use Magic Mushroom ingredients

If you have a question, how are mushrooms consumed? We will discuss it in this section. How to consume drugs Mushrooms are fresh or dried, or they can be brewed as tea or consumed with cigarettes or marijuana. These drug mushrooms can also be used in foods or cooked alone and then consumed. Psilocybin mushroom can be dried and made into a powder and put into a capsule and swallowed. Of course, the injection of this mushroom has also been seen in some cases, but this method is very rare. For this reason, injecting psilocybin powder is very dangerous and can be fatal.